Clinical Trials
69 trialsMK-3475-G21
Merck Sharp & Dohme LLC
A Study to Evaluate the Safety and Pharmacokinetics of Eflapegrastim in Pediatric Participants With Solid Tumors or Lymphomas and Treated With Myelosuppressive Chemotherapy
Spectrum Pharmaceuticals, Inc
Study of Rondecabtagene Autoleucel in Aggressive Large B-Cell Lymphoma
Lyell Immunopharma, Inc.
A Study of ELA026 in Participants With Relapsed/Refractory (R/R) T/NK Cell Malignancies (TCMs)
Electra Therapeutics Inc.
PRIMAVERA
AstraZeneca
xDRIVE for Florida-based Cancer Patients
First Ascent Biomedical Inc.
MK-3475-051
Merck Sharp & Dohme LLC
DAHLIA
Recursion Pharmaceuticals Inc.
EPCOREâ„¢FL-2
Genmab
GLOBRYTE
Hoffmann-La Roche
Safety, Pharmacokinetics, and Clinical Activity of LP-284 in Adult Patients With Relapsed or Refractory Lymphomas and Solid Tumors
Lantern Pharma Inc.
A Study Evaluating the Safety and Efficacy of Glofitamab + Gemcitabine + Oxaliplatin in U.S. Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Hoffmann-La Roche
Dose Escalation and Dose Expansion Study of MDX2003 in Patients With Different Types of Lymphoma
ModeX Therapeutics, An OPKO Health Company
Study of SLS009 (Formerly GFH009) a Potent Highly Selective CDK9 Inhibitor in Patients With Hematologic Malignancies and High-Risk Newly Diagnosed AML
Sellas Life Sciences Group
KinLET
ITM Solucin GmbH
Trial to Evaluate the Safety & Tolerability of JBZ-001 in Pts With Advanced Solid and Hematological Malignancies
Jabez Bioscience, Inc
A Study of DR-01 in Subjects With Large Granular Lymphocytic Leukemia or Cytotoxic Lymphomas
Dren Bio
CA-4948-101: Open-Label, Dose Escalation and Expansion Trial of Emavusertib (CA-4948) in Relapsed or Refractory Primary Central Nervous System Lymphoma (R/R PCNSL)
Curis, Inc.
Safety and Efficacy of Ponatinib for Treatment of Pediatric Recurrent or Refractory Leukemias, Lymphomas or Solid Tumors
Incyte Corporation
OPAL
AVM Biotechnology Inc
A Study of NX-5948 in Adults With Relapsed/Refractory B-cell Malignancies
Nurix Therapeutics, Inc.
A Study of NX-5948 in Adults With CLL/SLL Previously Treated With a Bruton's Tyrosine Kinase Inhibitor and a B-cell Lymphoma-2 Inhibitor (DAYBreak CLL-201)
Nurix Therapeutics, Inc.
TERZO
SecuraBio
QUADvance
AvenCell Therapeutics, Inc.
Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19)
Vironexis Biotherapeutics Inc.
A Study of Carmustine With and Without Ethanol in Subjects With Lymphoma
VIVUS LLC
TLN-121 in Relapsed or Refractory Non-Hodgkin Lymphomas
Treeline Biosciences, Inc.
A Study of the Efficacy and Safety of Lisocabtagene Maraleucel (Liso-cel) as First-Line Therapy in Adults With Transplant-Ineligible Primary Central Nervous System Lymphoma
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
A Study of NX-2127 in Adults With Relapsed/Refractory B-cell Malignancies
Nurix Therapeutics, Inc.
PiNACLE-H2H
Lyell Immunopharma, Inc.
A First-in-Human Study of HLA-Partially to Fully Matched Allogenic Cryopreserved Deceased Donor Bone Marrow Transplantation for Patients With Hematologic Malignancies
Ossium Health, Inc.
A Study of Brentuximab Vedotin With Doxorubicin, Vinblastine and Dacarbazine in Adults With Hodgkin Lymphoma in India
Takeda
A Safety and Efficacy Study of HCB101, Fc-fusion Protein Targeting SIRPα-CD47 Pathway, in Solid or Hematological Tumors
FBD Biologics Limited
POTENTIAL-M
NOBO Medicine
Dose-finding and Dose Expansion Study of OSE-279 in Subjects With Advanced Solid Tumors or Lymphomas
OSE Immunotherapeutics
CAMPERR
Adela, Inc
A Phase 1 Study of UB-VV111 With and Without Rapamycin in Relapsed/Refractory CD19+ B-cell Malignancies
Umoja Biopharma
Study of ZG005 in Combination With Gecacitinib in Patients With Relapsed or Refractory Lymphoma
Suzhou Zelgen Biopharmaceuticals Co.,Ltd
ON-5001
OncoNano Medicine, Inc.
A Study of Repotrectinib in Pediatric and Young Adult Subjects Harboring ALK, ROS1, OR NTRK1-3 Alterations
Turning Point Therapeutics, Inc.
A Safety and Efficacy Study Evaluating CTX112 in Subjects With Relapsed or Refractory B-Cell Malignancies
CRISPR Therapeutics
VIPER101
Vittoria Biotherapeutics
A Study of TLN-254 in Participants With Relapsed or Refractory T-cell Lymphoma
Treeline Biosciences, Inc.
IKS03 in Patients With Advanced B Cell Non-Hodgkin Lymphomas
Iksuda Therapeutics Ltd.
Phase 1 Trial of ST-001 nanoFenretinide in Relapsed/Refractory T-cell Non-Hodgkin Lymphoma
SciTech Development, Inc.
BCMA-CD19 cCAR in Multiple Myeloma and Plasmacytoid Lymphoma
iCell Gene Therapeutics
A Study to Assess the Safety and Efficacy of LB1410 in Participants With Advanced Solid Tumor or Lymphoma(Keyplus-001)
L & L Bio Co., Ltd., Ningbo, China
HOPE
Ossium Health, Inc.
APOLLO
Marker Therapeutics, Inc.
STARLIGHT-1
Estrella Immunopharma, Inc.